Loading...
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DRRX’s FA Score shows that 0 FA rating(s) are green whileRDY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DRRX’s TA Score shows that 5 TA indicator(s) are bullish while RDY’s TA Score has 6 bullish TA indicator(s).
DRRX (@Pharmaceuticals: Other) experienced а +0.65% price change this week, while RDY (@Pharmaceuticals: Other) price change was +4.39% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.94%. For the same industry, the average monthly price growth was +25.68%, and the average quarterly price growth was +18764.06%.
DRRX is expected to report earnings on May 09, 2023.
RDY is expected to report earnings on Jul 25, 2024.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
DRRX | RDY | DRRX / RDY | |
Capitalization | 33.1M | 12.5B | 0% |
EBITDA | -33.66M | 84.9B | -0% |
Gain YTD | 55.237 | 6.381 | 866% |
P/E Ratio | N/A | 19.68 | - |
Revenue | 9.19M | 271B | 0% |
Total Cash | 39M | 72.4B | 0% |
Total Debt | 23.2M | 19.9B | 0% |
DRRX | RDY | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 22 | |
SMR RATING 1..100 | 99 | 45 | |
PRICE GROWTH RATING 1..100 | 65 | 47 | |
P/E GROWTH RATING 1..100 | 100 | 71 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DRRX's Valuation (54) in the Pharmaceuticals Other industry is somewhat better than the same rating for RDY (90) in the Pharmaceuticals Generic industry. This means that DRRX’s stock grew somewhat faster than RDY’s over the last 12 months.
RDY's Profit vs Risk Rating (22) in the Pharmaceuticals Generic industry is significantly better than the same rating for DRRX (100) in the Pharmaceuticals Other industry. This means that RDY’s stock grew significantly faster than DRRX’s over the last 12 months.
RDY's SMR Rating (45) in the Pharmaceuticals Generic industry is somewhat better than the same rating for DRRX (99) in the Pharmaceuticals Other industry. This means that RDY’s stock grew somewhat faster than DRRX’s over the last 12 months.
RDY's Price Growth Rating (47) in the Pharmaceuticals Generic industry is in the same range as DRRX (65) in the Pharmaceuticals Other industry. This means that RDY’s stock grew similarly to DRRX’s over the last 12 months.
RDY's P/E Growth Rating (71) in the Pharmaceuticals Generic industry is in the same range as DRRX (100) in the Pharmaceuticals Other industry. This means that RDY’s stock grew similarly to DRRX’s over the last 12 months.
DRRX | RDY | |
---|---|---|
RSI ODDS (%) | 1 day ago77% | 1 day ago55% |
Stochastic ODDS (%) | 1 day ago79% | 1 day ago56% |
Momentum ODDS (%) | 1 day ago83% | 1 day ago47% |
MACD ODDS (%) | 1 day ago85% | 1 day ago57% |
TrendWeek ODDS (%) | 1 day ago82% | 1 day ago52% |
TrendMonth ODDS (%) | 1 day ago88% | 1 day ago48% |
Advances ODDS (%) | 1 day ago82% | 5 days ago53% |
Declines ODDS (%) | 5 days ago86% | 3 days ago49% |
BollingerBands ODDS (%) | 1 day ago83% | 1 day ago69% |
Aroon ODDS (%) | 1 day ago88% | 1 day ago39% |
A.I.dvisor indicates that over the last year, DRRX has been loosely correlated with ANIP. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if DRRX jumps, then ANIP could also see price increases.
Ticker / NAME | Correlation To DRRX | 1D Price Change % | ||
---|---|---|---|---|
DRRX | 100% | +3.67% | ||
ANIP - DRRX | 42% Loosely correlated | -0.73% | ||
UPC - DRRX | 27% Poorly correlated | +7.74% | ||
SNDL - DRRX | 24% Poorly correlated | -2.50% | ||
OGI - DRRX | 22% Poorly correlated | -3.63% | ||
ACB - DRRX | 22% Poorly correlated | -6.81% | ||
More |
A.I.dvisor tells us that RDY and TAK have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and TAK's prices will move in lockstep.
Ticker / NAME | Correlation To RDY | 1D Price Change % | ||
---|---|---|---|---|
RDY | 100% | +4.37% | ||
TAK - RDY | 30% Poorly correlated | -1.21% | ||
SNDL - RDY | 24% Poorly correlated | -2.50% | ||
TEVA - RDY | 23% Poorly correlated | +1.84% | ||
ACET - RDY | 23% Poorly correlated | -3.47% | ||
ACB - RDY | 22% Poorly correlated | -6.81% | ||
More |